Evidence map›Paper›PMID 41980919›Full record

Trial reportSignal transduction and targeted therapy2026

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

Benoist Chibaudel, Louis-Marie Dourthe, Thierry André, Julie Henriques, Vincent Bourgeois, Pierre-Luc Etienne, Jérôme Desramé, Elisabeth Carola, Olivier Dupuis, Nabil Baba-Hamed and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01910610 (Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01910610 phase3unknown statusnot on this map

Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.

TypeinterventionalSponsorGERCOR - Multidisciplinary Oncology Cooperative GroupRan2013 to 2024Enrolled464ConditionsColorectal Cancer MetastaticArmsFOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Benoist ChibaudelDepartment of Medical Oncology, Hôpital Franco-Britannique, Fondation Cognacq-Jay, Cancérologie Paris Ouest, Levallois-Perret, France. benoist.chibaudel@cognacq-jay.fr.ORCID http://orcid.org/0000-0003-1279-2044
Louis-Marie DourtheClinique Sainte-Anne, Strasbourg, France.
Thierry AndréDepartment of Medical Oncology, Saint-Antoine Hospital, Sorbonne University, APHP, Paris, France.ORCID http://orcid.org/0000-0002-5103-7095
Julie HenriquesMethodology and Quality of Life Unit in Oncology, University Hospital of Besançon; Université de Franche-Comté, EFS, INSERM UMR RIGHT, Besançon, France.
Vincent BourgeoisDigestive Oncology, Hôpital Duchenne, Boulogne-Sur-Mer, France.
Pierre-Luc EtienneMedical Oncology Department, Hôpital Privé des Côtes d'Armor, Plerin, France.
Jérôme DesraméHôpital Privé Jean Mermoz, Lyon, France.
Elisabeth CarolaPôle d'Oncologie Médicale, Groupe Hospitalier Public du Sud de l'Oise, Creil, France.
Olivier DupuisClinique Victor Hugo, Le Mans, France.
Nabil Baba-HamedMedical Oncology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France.
Dominique AubyDepartment of Medical Oncology, CH de Mont‑de‑Marsan Hospital Layné, Mont‑De‑Marsan, France.
Christophe LouvetMedical Oncology Department, Institut Mutualiste Montsouris, Paris, France.
Emmanuel MaillardCentre Hospitalier Annecy-Genevois Site Annecy, Pringy, France.
Olivier RomanoMedical Oncology Department, Lille Metropole Cancer Institute, Hôpital Privé Villeneuve D'ascq, Villeneuve D'ascq, France.
Christophe TournigandDepartment of Medical Oncology, Henri Mondor University Hospital, Créteil, France.
Marie-Line Garcia-LarnicolDepartment of Medical Oncology, Saint-Antoine Hospital, Sorbonne University, APHP, Paris, France.
Einat Shacham-ShmueliCancer Center, Chaim Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Brian Healey BirdBon Secours Hospital Cork, Cancer Trials Ireland and University College Cork, Cork, Ireland.ORCID http://orcid.org/0000-0001-8562-0564
François GhiringhelliMedical Oncology Department, Centre Georges-François Leclerc, University of Bourgogne Franche-Comté, Dijon, France.
Aimery de GramontDepartment of Medical Oncology, Hôpital Franco-Britannique, Fondation Cognacq-Jay, Cancérologie Paris Ouest, Levallois-Perret, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing unresectable metastatic colorectal cancer (mCRC) requires a comprehensive strategy. While chemotherapy, anti-angiogenic, and anti-epidermal growth factor receptor (EGFR) agents are available, strategy trials are needed to optimize their use and sequencing. The STRATEGIC-1 phase III trial (NCT01910610) was designed to determine the optimal treatment sequence in patients with untreated, unresectable wild-type RAS/BRAF

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsProto-Oncogene Proteins B-rafAdultAgedBevacizumabCamptothecinCetuximabFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedNeoplasm MetastasisBevacizumabBRAF protein, humanCamptothecinCetuximabFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsProto-Oncogene Proteins B-raf

Identifiers

PMID41980919
PMCPMC13079909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.